Absci Corporation (ABSI) Stock Analysis & Investment Frameworks
Absci Corporation (ABSI) stock analysis on Invetso. Review Absci Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Absci Corporation Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Absci Corporation Key Financial Metrics
- Market Cap: $1.58B
- Revenue: $2.80M
- ROE: -59.21%
- ROIC: -52.24%
- Dividend Yield: N/A
About Absci Corporation
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Absci Corporation Investment Frameworks
Invetso analyzes Absci Corporation (ABSI) across the following frameworks:
- Absci Corporation 10Y Growth Potential
- Absci Corporation Scenario Analysis
- Absci Corporation Risks & Opportunities
- Absci Corporation Economic Moat
- Absci Corporation Business Model
- Absci Corporation Management
- Absci Corporation SWOT Analysis
- Absci Corporation Porter's 5 Forces
- Absci Corporation PESTLE Analysis
- Absci Corporation ESG Analysis